Newly diagnosed multiple myeloma patients who use Revlimid (lenalidomide) as a maintenance therapy after a stem cell transplant live significantly longer than those receiving a placebo or nothing, a meta-analysis shows. The research deals with autologous stem cells, or those taken from a patient’s own body. Scientists refer to such transplants as ASCTs.
PharmaMar is launching a clinical trial to explore its investigational therapy Aplidin (plitidepsin) in a quadruple combination treatment for multiple myeloma. The four compounds involved in the combo all have different ways to attack the cancer, allowing better results than individual therapies, according to PharmaMar. Aplidin, compared to most cancer treatments, does…
NantKwest’s Vax-DC/MM cell therapy has induced a partial or complete response in 42 percent of relapsed or refractory multiple myeloma (MM) and lymphoma patients in a Phase 1 clinical trial (NCT02248402). The findings showed no evidence of severe adverse events. Results of this work were published under the title “…
The U.S. Food and Drug Administration (FDA) has approved Imbruvica (ibrutinib) for the treatment of chronic graft-versus-host-disease (cGVHD), a common complication of stem cell or bone marrow transplant, in adult patients who failed to respond to other treatments. The FDA approval makes Imbruvica the first and only medicine specifically approved for cGVHD…
Sutro Biopharma‘s STRO-001 eliminates or significantly slows the growth of non-Hodgkin lymphoma and multiple myeloma tumors, studies in mice indicate. Sutro expects the results to support its investigational new drug application for STRO-001. The U.S. Federal Drug Administration must approve the application before the company can start clinical trials of the…
Revlimid (lenalidomide) therapy maintenance has been shown to delay disease progression and extend survival in newly diagnosed multiple myeloma (NDMM) patients who receive a transplant of their own blood-forming stem cells, called autologous stem-cell transplantation (ASCT). The findings include data of 1,208 NDMM patients and were reported in a study…
Stem cell transplants derived from patients’ own bone marrow are a safe and effective treatment for those with multiple myeloma who fail to respond to first-line treatments, a study reports. Scientists call transplants using patients’ own cells autologous hematopoietic stem cell transplants, or Auto-HCTs. The study, “Outcome of…
The Cancer Support Community (CSC), a nonprofit advocacy organization, recently released a research report about the emotional, social, and financial burdens on cancer patients. The survey found that gaps in communication between patients and care teams about cost of care resulted in “financial toxicity” for people living with cancer. “…
Kyprolis (carfilzomib), when given with dexamethasone, lets relapsed myeloma patients live an average 7.6 months longer than those treated with Velcade (bortezomib) with dexamethasone — information that Amgen, which makes Kyprolis, hopes to include in the treatment’s prescription label. The company has applied to both the U.S. Food and Drug Administration and the…
Adding the proteasome inhibitor Kyprolis (carfilzomib) to the standard regimen of Revlimid (lenalidomide) and dexamethasone reduced the risk of death in patients with relapsed multiple myeloma by 21%, according to results from the final analysis of the Phase 3 ASPIRE trial (NCT01080391).
Get regular updates to your inbox.